E40, a novel microbial protease efficiently detoxifying gluten proteins, for the dietary management of gluten intolerance

Linda Cavaletti1, Anna Taravella1, Lucia Carrano1, Giacomo Carenzi1, Alessandro Sigurtà1, Nicola Solinas1, Salvatore De Caro2, Luigia Di Stasio2, Stefania Picascia3, Mariavittoria Laezza3, Riccardo Troncone4, Carmen Gianfrani3,4 & Gianfranco Mamone2

Gluten proteins are the causative agent of Celiac Disease (CD), a life-long food intolerance characterized by an autoimmune enteropathy. Inadvertent gluten exposure is frequent even in celiac patients complying with a gluten-free diet, and the supplementation of exogenous gluten-digestive enzymes (glutenases) is indeed a promising approach to reduce the risk of dietary gluten boost. Here we describe Endopeptidase 40, a novel glutenase discovered as secreted protein from the soil actinomycete Actinoallomurus A8, and its recombinant active form produced by Streptomyces lividans TK24. E40 is resistant to pepsin and trypsin, and active in the acidic pH range 3 to 6. E40 efficiently degrades the most immunogenic 33-mer as well as the whole gliadin proteins, as demonstrated by SDS-PAGE, HPLC, LC-MS/MS, and ELISA. T lymphocytes from duodenal biopsies of celiac patients showed a strongly reduced or absent release of IFN-γ when exposed to gluten digested with E40. Data in gastrointestinal simulated conditions suggest that no toxic peptides are freed during gluten digestion by E40 into the stomach to enter the small intestine, thus counteracting the intestinal inflammatory cascade to occur in CD patients. E40 is proposed as a novel candidate in Oral Enzymatic Therapy for the dietary management of gluten toxicity.

Celiac Disease (CD) is a chronic autoimmune enteropathy, with a defined environmental trigger in the form of gluten proteins contained in wheat and related cereals1. Gluten intolerance affects genetically predisposed patients carrying the HLA DQ2/DQ8 genes, with a prevalence estimated approximately 1% in wheat consuming countries1. The small intestinal mucosa of subjects with acute CD shows increased numbers of intraepithelial lymphocytes, villous atrophy, crypts hyperplasia, and a chronic inflammatory status2. Gluten is a heterogeneous mixture of insoluble proteins, consisting of gliadins and glutenins present in wheat, rye and barley cereals3. The high proline and glutamine residue content renders the gluten proteins largely inaccessible to human proteases of the gastrointestinal tract. This allows large proline/glutamine rich peptides to reach the small intestine and trigger immune responses in patients with CD4,5. These undigested peptides can cross the small intestine mucosal barrier reaching the lamina propria where they are deamidated by tissue transglutaminase (tTG)6. The deamidated gluten peptides do especially trigger both humoral and T-cell mediated adaptive immune responses7. To date, several T-cell stimulatory peptides, resistant to gastrointestinal digestion, have been identified either in gliadin and glutenin proteins8, though a 33-mer from α-gliadin is currently considered the most immunogenic peptide, as it includes six overlapping epitopes4.

Life-long adherence to a strict gluten-free diet (GFD) is the only effective treatment available for CD patients9. However, many patients fail to respond to GFD either clinically or histologically. Several surveys highlight the psychosocial implications of adherence to a GFD, hence, efforts are ongoing to develop supplemental strategies to support GFD or therapeutic approaches beyond the GFD10. Total gluten avoidance is pragmatically impossible.
due to gluten ubiquity in food industry, even in CD subjects strictly committed to the GFD. Novel therapies, aimed at rendering gluten harmless and improving CD patient quality of life, have been intensively investigated. A major area of research is the development of enzyme preparations able to digest the toxic fragments of gluten in the stomach, thus preventing exposure of these fragments to the intestinal mucosa. To this end, endopeptidases produced by various plants, bacteria, or fungi have been studied and demonstrated to degrade at different extent the proline/glutamine rich gluten peptides in the gastric and upper intestinal tracts, thus "detoxifying" gluten. These novel enzymes, termed "glutenases", could be devised as oral supplements, supporting the GFD and protecting from unintentional gluten exposures. Previous in vitro studies demonstrated that some of these glutenases are efficient in catalyzing the digestion of gluten proteins in acidic condition, reporting degradation of up to 70–99% of gluten protein load. All the experimental conditions set-up to assess gluten detoxification forecast to test a glutenase in combination with the gastric enzyme pepsin, to obtain a complete gluten degradation in the first gastrointestinal tract. As the main goal of the Oral Enzymatic Therapy (OET) is to rapidly detoxify gluten proteins and, above all, preferably during the transit in the stomach, the availability of proteases directly and efficiently detoxifying gluten even irrespective of pepsin partial gluten-digestion, would be very promising to this respect.

Here, we present the acid and pepsin-resistant Endoprotease 40 (E40), a novel glutenase originally discovered as secreted protease from the acidophilic actinomycete Actinoallomurus A8 (International patent WO 2013/083338). Actinomycetes, a group of soil inhabitant filamentous bacteria, are an interesting source of proteases. In particular, acidophilic actinomycete strains, which grow in acidic environments, are expected to express extracellular proteases with enzymatic properties suitable for OET in CD. E40 was expressed as recombinant protein in Streptomyces lividans TK24 strain and its glutenase activity was comprehensively assessed by proteomic, enzymatic and immunological approaches. The data gathered are critically discussed and statistically evaluated with the final aim to demonstrate the potentiality of E40 as a novel candidate for OET in CD.

Results
Discovery of endopeptidase E40 from the actinomycete Actinoallomurus A8 and assessment of its glutenase activity.

E40 was discovered as a new secreted protease from a newly isolated strain, labeled A8, assessed by 16S rRNA gene sequencing to belong to the genus Actinoallomurus, whose members grow optimally at pH values close to 5. Actinoallomurus A8 was isolated from a soil with pH 4.2 collected in the north of Italy (supplementary material, Figs S1 and S2). The whole genome sequence of Actinoallomurus A8, whose members grow optimally at pH 4.2 collected in the north of Italy (supplementary material, Figs S1 and S2). E40 purified from A8 culture supernatant (corresponding to “<100 kDa” fraction), had an enzymatic activity in the range of pH 3–6 with optimum at pH 5 (Fig. 1, panel A). At this environmental condition, E40 showed a marked glutenase activity since gliadin proteins were completely digested (Fig. 1, panel B). E40 coding gene identification (e40, accession number MK303398, Fig. S3) was carried out by genome sequence of whole Actinoallomurus A8 genome and by MudPit analysis of the “<100 kDa” fraction. The resulting E40 whole gene translation predicted a protein consisting of 398 amino acid residues, belonging to the serine-carboxyl peptidase S53 family (as revealed by Blast analysis), with the catalytic triad formed by aspartic acid, glutamic acid and serine at positions 156, 160 and 329, respectively (Fig. 2). Notably, the presence of aspartic acid instead of histidine, which is typical of the serine proteases catalytic triad, and the presence of a further aspartic residue in the active site position 231, confirms E40 the capability to hydrolyze at low pH value.

The signalP 4.1 server analysis identified the N-terminal signal peptide between positions 27 and 28, and predicted that the mature form started from position 74, resulting in an expected 32.5 kDa mature enzyme (Fig. 2).
Cloning and expression of E40 coding gene in *S*. *lividans* TK24/plJ86.

E40 coding gene was successfully cloned in *Streptomyces lividans* TK24, using the pIJ86 expression vector (Fig. S4). The recombinant E40 (rE40) producing *S*. *lividans* TK24/pIJ86/e40 was cultivated in an animal origin supplement-free medium. The monitoring of the enzymatic activity in culture supernatant at flask level demonstrated a stable and continuous production of rE40, up to 8 days of fermentation (Fig. 3, panel A). As per its wild form, rE40 was active in the pH range 3–6, with an optimum at pH 5 (Fig. 3, panel B). The zymographic analysis, carried out at pH 5, demonstrated that rE40 was the only active protein in culture supernatants (Fig. 3, panel C).

**Figure 2.** Aminoacid sequence of E40. Sequence labeled with aminoacid numbering from the N-terminus of the whole protein. 1–27 (red): putative signal peptide sequence (according to signalP 4.1 server prediction), 28–73 (blue): putative pro-enzyme sequence, 74–398 (black): mature form. Aminoacids partecipating to the active site are indicated by asterisks; in black, the putative catalytic triad.

**Figure 3.** Expression of E40 as active secreted protease by *S*. *lividans* TK24/plJ86/e40 submerged fermentation at flask scale (panels (A–C)) or in 15 L bioreactor, with subsequent E40 purification (panels (D and E)). (A) Activity of supernatant samples taken at different fermentation times from the producing *S*. *lividans* TK24/plJ86/E40 (E40, continuous line) and absence of activity from the plJ86-empty control strain (ctr, dashed lines). ◆72, ▴96, ●168, ◼192 fermentation hours. Activity toward the substrate sucAAPF-AMC at pH5 is shown as relative fluorescent units (Y axis) produced in time (X axis). (B) Activity showed by the 168 hours supernatant (SN) sample at different pH, showing the optimum at pH5. (C) Zymograhy of the 168 h sample at pH5, using the same substrate as in panel (A) and visualized under UV light. (D) Profile of purified E40 from the 15L fermentation, lane 1: final E40 preparation stained with Coomassie (the red arrow indicates E40), lane 2: zymography as in (C), lane 3: band of gelatin hydrolysis after 2 hours of digestion at 37 °C and pH5, visualized after Coomassie staining of the gelatin substrate.
The final powder obtained after the fermentation and the downstream purification process scaled at 15 L volume, contained 6% total proteins with specific rE40 activity of 41.000 U/mg. The purified rE40 had chemical/physical properties and bioactivity as per the wild-type form. The efficiency of the purification process was demonstrated by SDS-PAGE, where rE40 migrated in the main band at ~40 kDa (Fig. 3, panel D, lane 1, red arrow) and was the only protein active toward the chromogenic substrate suc-Ala-Ala-Pro-Phe-AMC (Fig. 3, panel D, lane 2). The N-terminal sequence analysis of the 40 kDa SDS-PAGE band confirmed the predicted mature form of rE40. rE40 was also the only protein active against a generic protein substrate like gelatin (Fig. 3, panel D, lane 3), thus excluding the presence of any endoprotease other than rE40 in the final enzymatic preparation. Activity of purified rE40 at different pH values was evaluated with the substrate suc-Ala-Ala-Pro-Phe-pNA, pH range 2 to 8 (Fig. 3, panel E). It resulted to be maximally active at pH 5 and significant residual activity (~40%) was maintained at pH 3. These results predict optimal action in a post-prandial gastric environment, when pH keeps higher than 3 for over an hour23,24. Interestingly, rE40 remains significantly active (approximately 50%) at pH 6, suggesting also a prolonged action into the post-prandial duodenal compartment where pH reduces to pH ≤ 6 for long time, after the meal24. Overall, our results support a perfect similarity between the wild and recombinant form of E40. For such reason and easiness of reading, the glutenase will be referred to as E40 in the following text.

E40 activity is resistant at in vitro gastrointestinal digestive milieu. The resistance of E40 to the proteolytic activity of gastric (pepsin) and duodenal (trypsin) digestive proteases was further evaluated (Fig. 4), using suc-Ala-Ala-Pro-Phe-pNA as substrate. Chymotrypsin was not included in the analysis, because active onto the same substrate. Noteworthy, either pepsin (Fig. 4, panels A–C) or trypsin (Fig. 4, panels D and E) did not hydrolyze the chromogenic substrate. E40 activity was assessed with and without pepsin (1:2 w/w ratio vs E40) in the pH range 4–5, and with or without trypsin (1:2 w/w ratio vs E40) in pH 6–7. Free pNA release from hydrolysis of the chromogenic substrate was monitored during reactions protracted for 110 minutes at 37 °C. Notably, E40 cleaving activity was unaffected either by pepsin/trypsin addition or by acidic pH. By contrast, a slightly enhanced E40 activity was observed in the presence of pepsin (Fig. 4, panels A–C), maybe due to unmasking of E40 catalitic site by pepsin. Overall, these findings confirm E40 resistance to the main human digestive proteases, at physiological conditions.

Pronounced digestion of the immunodominant 33-mer peptides and gliadin proteins by E40. The 33-mer degradation was monitored by LC-MS/MS before (Fig. 5, panel A) and after (Fig. 5, panels B–E) E40 digestion over 0–60 minutes of incubation (0′–60′, E40:33-mer molar ratio of 1:48). Notably, a slight hydrolysis of 33-mer was observed as soon as the incubation started (Fig. 5, panel B, 0 minutes), whilst the native peptide signal
completely disappeared after only 15 minutes (Fig. 5, panel C). More specifically, the MS/MS spectra analysis demonstrated that E40 activity broke down all the 33-mer immunotoxic sequences (Fig. 5, panel F). E40 cleaving site occurred between F-P and Q-L, leading to short peptides lacking of T-cell stimulatory capacity. This finding was also observed at more diluted E40 concentration (1:96, molar ratio), and complete 33-mer degradation took 30 minutes (not shown). Further, the ability of E40 to hydrolyze harmful peptides in whole gliadin proteins was assessed by HPLC analysis (Fig. 6). Because of the complex mixture of whole gliadins, digestion with E40 (1:48, molar ratio) was extended up to 240 minutes of incubation (Fig. 6, panels B–F). Undigested gliadin sample was run as reference control (Fig. 6, panel A). As expected, the chromatographic profile was drastically changed, since peaks assigned to α-, β-, and γ-gliadin were markedly reduced after 30 min (panel C) and disappeared between 60 and 120 min of E40 digestion (panel D and E). The profiles of digested products at 180 min and 240 min (panel F and G) were similar, indicating that no further degradation arose.

**Assessment of E40 proteolytic degradation of humoral and T-cell gluten epitopes by G12 ELISA and celiac mucosa T cells.** We next evaluated whether E40 enzymatic activity efficiently neutralizes: i) the capacity of gluten proteins to bind G12 antibodies, and ii) the stimulation of a T-cell-mediated immune response, measured by IFN-γ release. To this purpose, gliadin proteins were digested with E40 alone, or with E40 co-incubated with the gastrointestinal proteases pepsin and trypsin/chymotrypsin, at different pH and time points as detailed in Table 1. To estimate the effect of E40 digestion on the immunological potential of wheat, gluten content of samples A-L was determined by the monoclonal antibodies specific for QPQLPY sequence (Elisa – G12).
Compared to untreated gliadin samples (I and L), E40 digested sample (from A to H) showed a drastic reduction of gluten content, well below 20 ppm (Table 1).

In order to evaluate the capability of gliadin preparations to activate a T-cell response, different gliadin enzymatic digests (sample A-L) were deamidated by tTG treatment, before being assayed on T cells. Highly responsive to gliadin epitopes, CD4+ T-cell lines previously established from intestinal biopsies of CD patients, were used as sensitive bioassay to test E40 detoxifying properties. Five different T-cell lines were selected on the base of their recognition pattern of gliadin peptides, covering the most immunogenic epitopes from all three gliadin families (α-, γ- and ω-gliadins) (Fig. 7, panels A–C). As expected, all the T cells lines produced high level of IFN-γ when exposed to pepsin-chymotrypsin/trypsin digested gliadin (samples I and L). Conversely, in all the experimental conditions examined, no detectable IFN-γ production was measured in T cells exposed to E40-digested gliadins.

To unequivocally exclude that inhibited IFN-γ production might result from an unspecific toxic response to E40, peripheral blood mononuclear cells (PBMCs) from healthy donors were stimulated with the mitogen phytohemagglutinin (PHA), in presence or absence of E40-gliadin digests (Fig. S5). Therefore, neutralization of the immune-stimulatory properties of gliadin peptides on human T cell, otherwise defined as gliadin detoxification, was specific to E40 proteolytic activity.

**Discussion**

It has been widely demonstrated that an abnormal immune response to gluten occurs in subjects with CD. HLA genes are the main predisposing factor for CD, although the risk genes are necessary but non-sufficient to determine the disease, and several environmental factors are required. In particular, gastrointestinal viral infections, factors disrupting gut barrier integrity and intestinal dysbiosis have a role in the incidence, progression...
and management of gluten intolerance\(^3\). The upstream cause is the incomplete hydrolysis of gluten proteins by human gastro-intestinal proteases. The pronounced resistance of gluten proteins to digestive process is not due to enzymatic deficiencies in celiac patients but rather to gluten's peculiar primary sequence, enriched of proline-glutamine residues, inefficiently cleaved by gastro-intestinal proteases\(^4\). The oral supplementation of exogenous endopeptidases, able to act synergistically with the physiological proteases in degrading gluten proteins, has been suggested as one of the most effective strategy to support gluten-free dietary treatments, in particular in case of inadvertent (unintentional) exposure to gluten. Several proteolytic enzymes are currently under investigations for their ability to degrade gluten under gastric conditions, and suitable for oral enzyme supplementation in CD. Particularly, three endopeptases have been more extensively tested for their efficacy in abolishing or reducing the T-cell immune-stimulatory capability\(^27-29\). A fast proteolytic activity at low pH (as occurring in the stomach), pepsin-resistance, and high specificity for breaking down proline and glutamine rich sequences characterizing the immunotoxic gluten peptides are the desired properties of optimal glutenases in OET. These combined properties should prevent that gluten peptides may reach the duodenal mucosa having maintained their immune-stimulatory form\(^30\). Latiglutenase (ImmunogenX, previously ALV003) is a combination of the gluten-specific endopeptase EP-B2 degrading complex gluten bread proteins, and a prolyl-endopeptidase (PEP) from Spirochetomonas capsulata, that detoxifies the residual oligopeptide products of EP-B2\(^31\). In a phase II trial, Latiglutenase has been shown to successfully degrade immunogenic gluten fragments in the stomach, and to attenuate mucosal injury in CD patients consuming up to 2 g gluten daily along with GFD\(^32\). The synthetic enzyme KumaMax30 had similar in vitro results to Latiglutenase, but is still under development\(^29,33\). AN-PEP, an Aspergillus niger derived prolyl-endopeptidase, had very promising in vitro, ex vivo, and in vivo results, and its safety has been recently demonstrated in clinics\(^28,34\).

In this promising scenario, we report the identification of the novel microbial Endopeptidase 40, that shows to be endowed with all the glutenasic properties needed for successful OET in CD. E40 was recombinantly expressed in the actinomycete heterologous host \(S.\) lividans TK24, a strain free from endogenous plasmids and lacking an outer membrane, therefore devoid of lypopolysaccharide endotoxins\(^35\).

The recombinant expression of E40 in \(S.\) lividans TK24 resulted in the secretion of active E40, confirming that the wild signal peptide has been recognized and the enzyme has been processed to maturation, exactly as done by the wild producer \(Actinomadura\) A8. As expected, all the chemico-physical characteristics and biological properties of the native form were maintained, e.g. stability and activity at post-prandial gastric pHs, resistance to pepsin digestion, high efficiency in the extensive degradation of the most immunogenic peptide of \(\alpha\)-gliadin, such as the Pro-Gln enriched 33mer peptide (LQLQPFPQPQLPYPQPQLPYPQPQPF), as well as of whole gliadin proteins\(^4,30\). MS/MS spectra analysis demonstrated E40 to break down all the six 33-mer immunotoxic epitopes, displaying an extremely fast cleaving activity at covalent bond on F-P and Q-L residues within 15 minutes of treatment, with no 33-mer signal detectable within 1 hour. Also whole gliadin proteins from hexaploid wheat were markedly proteolized within 1 hour of E40 digestion. The absence of immunogenic potential of the pool of peptidic fragments produced during E40 digestion of wheat gliadin was assessed via G12 moAb competitive ELISA, specific to detect gluten immune-stimulatory peptides having the QPQLPY sequence. The validated human T-cell assay further confirmed that no residual immune-toxicity remains in E40-digested gluten.

Noteworthy, E40 gluten-degrading activity is independent from pepsin proteolysis. Our findings demonstrated that E40 conveys the desired property to get a fast gluten gastric digestion, thus speeding up the breaking down of immunotoxic peptides particularly into the stomach. This observation, and the comprehensive micro-biological, proteomic and immunological analyses performed in our study, candidates E40 to be a fast-acting and strongly efficient glutenase. Due to the fact that the GFD is indeed restrictive for many celiac subjects that are not compliant with the dietary therapy, the availability of E40 as an adjuvant enzymatic compound favoring the complete and rapid digestion of gluten proteins would be of great benefit to people in need of adhering to a GFD, but anyhow exposed to the risk of inadvertent gluten exposure. Further \(in\) \(vivo\) and human studies are currently planned to confirm the efficacy of E40-based OET for CD. Furthermore, it will be of interest to also assess E40 utility in the dietary management of other gluten-related disorders\(^36\). In this context, it is noteworthy that Streptomyces, used to produce the recombinant E40, are regarded as a safe source of proteins for human alimentary use. Two examples of food enzymes sourced from Streptomyces spp are: glucose isomerases used for fructose

| Gliadin digest sample | Gastric hydrolysis condition | Duodenal hydrolysis condition | ppm (ng/mL) |
|-----------------------|-----------------------------|-----------------------------|------------|
| A                     | E40 (1h) (pH 4)             |                             | 1.72       |
| B                     | E40 (2h) (pH 4)             |                             | 2.26       |
| C                     | E40 + Pepsin (1h) (pH 4)    |                             | 5.23       |
| D                     | E40 + Pepsin (2h) (pH 4)    |                             | 5.42       |
| E                     | E40 + Pepsin (2h) (pH 4)    | Trypsin + Chymotrypsin (2h) (pH 6) | 4.09       |
| F                     | E40 + Pepsin (2h) (pH 4)    | Trypsin + Chymotrypsin (4h) (pH 6) | 2.68       |
| G                     | E40 + Pepsin (1h) (pH 4)    | Trypsin + Chymotrypsin (2h) (pH 6) | 1.68       |
| H                     | E40 + Pepsin (1h) (pH 4)    | Trypsin + Chymotrypsin (4h) (pH 6) | 2.05       |
| I                     | Pepsin (2h) (pH 4)          | Trypsin + Chymotrypsin (4h) (pH 6) | >800       |
| J                     | Pepsin (2h) (pH 4)          | Trypsin + Chymotrypsin (4h) (pH 7) | >800       |

Table 1. Enzymatic digestion scheme of gliadin proteins by pepsin-trypsin/chymotrypsin and E40, and determination of gluten content of digested gliadin sample A-L (see Table 1) by G12-Elisa assay.
syrup production\textsuperscript{37}, and the widely exploited transglutaminase from \textit{S. mobaraensis}, used in food industry for its properties in improving the texture and overall quality of final food products, such as processed meat and fish products, as well as diary and baked food\textsuperscript{38}.

In conclusion, we have provided evidences the new E40 glutenase efficiently degrades the most immune-toxic gluten peptides, at acidic and gastrointestinal simulating conditions. The availability of adjuvant enzymes capable of effectively degrading gluten proteins during their transit into the first gastrointestinal tract, and particularly into the stomach, would have a great relevance to prevent the adverse inflammatory response induced by gluten, in intolerant individuals\textsuperscript{4}.

**Materials and Methods**

**Reagents.** Actinomycete strain \textit{Actinoallomurus A8} was from the collection of “Fondazione Istituto Insubrico di Ricerca per la Vita” laboratory. The N-Succinyl-Ala-Ala-Pro-Phe p-nitroanilide (suc-Ala-Ala-Pro-Phe-pNA) and N-Succinyl-Ala-Ala-Pro-Phe-7-aminomethyl coumarine (suc-Ala-Ala-Pro-Phe-AMC) were from Bachem (Bubendorf, Switzerland), pepsin, trypsin, nalidixic acid, and apramycin were from Sigma-Aldrich (Milan, Italy), mannitol was from Carlo Erba (Cornaredo, Italy), soya flour was from Cargill (Padova, Italy), agar and soy peptone were from Conda (Madrid, Spain), sucrose and glucose were from VWR (Leuven, Belgium), yeast and malt extracts were from BD (Franklin Lakes, NJ, USA) and Costantino (Favria, TO, Italy) respectively, the 33-mer a-gliadin peptide was synthesized by Biotem (Apprieu, France). All other reagents used for cloning of the endopeptase were of analytical reagent grade. Strain \textit{S. lividans} TK 24 and expression vector pIJ86 were from the John Innes Center (Norwich, UK). Protein concentration was measured by BCA assay (Thermo Scientific, Rodano, MI, Italy).

**Figure 7.** The digestion with E40 strongly reduced the immunostimulatory capacity of gliadin on intestinal T cells. Gliadin purified from hexaploid wheat was treated with E40 in the absence (samples A and B) and in presence of gastrointestinal proteases (samples C–E) at the conditions specified in Table 1. The enzymatic digests of gliadin were next deamidated by tTG treatment and assayed for the stimulatory capability on intestinal T cells. T-cell activation was determined by the measurements of IFN-\textgamma{} production. All gliadin digests were assayed at 50 and 100\textmu{}g/ml. (A) Gliadin reactive T-cell lines obtained from jejunal biopsies of 5 different celiac subjects were assayed for recognition of E40-treated gliadin (samples A–H). Autologous EBV-transformed B cells were used as antigen presenting cells. Untreated gliadin digests (samples I and L) and phytohemagglutinin (PHA) were used as positive controls. Each panel is a representative experiment out of three done for each T-cell line. (B) Percent of T-cell response to E40-treated gliadin digests were calculated on the E40-untreated gliadin digests (sample I). The data are mean responses of T-cell lines from 5 different CD patients. (C) Characteristic of CD subjects enrolled in the study as source of gliadin-reactive intestinal T-cell lines. The profile of gliadin peptides recognized by each T-cell line is reported. Unpaired Student T test was used to assess the statistical significance. *\textit{p} < 0.05.
Enzyme activity assay. Enzymatic activity was performed in 96-well microtiter plates (transparent, flat-bottom) using the Infinite 200 PRO plate reader (Tecan, Männedorf, CH). Twenty microliters of enzyme samples (concentration range 10–50 nM) were pre-incubated for 5 min at 37 °C and then added to 180 μl of 220 μM succ-Ala-Ala-Pro-Phe-pNA in citrate phosphate buffer (0.1 M citric acid, 0.2 M disodium hydrogen phosphate, pH 5). Samples were incubated for 20 minutes at 37 °C. The pNA was detected at 410 nm, reading at intervals of 5 min. One Unit was defined as the amount of enzyme that released 1 μmol of pNA per minute, sample activity was expressed as enzyme Units per ml of supernatant or per mg of protein.

The pH optimum was determined using the same substrate which was prepared in 0.2 M ammonium citrate for pH 2 or citrate phosphate buffer at pH range 3–8, respectively.

Wild Endopeptidase E40 discovery and gene identification. Wild E40 was produced as extracellular protein by submerged fermentation of strain A8, an actinomycete strain belonging to the genus Actinomallomurus, well growing at pH close to 5.5. The discovery and purification of Endopeptidase E40, as well as the cloning/ expression and purification of its recombinant form are described in Supplemental Material.

Zymography analysis. E40 containing samples were run by non-reducing SDS-PAGE (12% polyacrylamide) at 100 V using a Tetra-cell Mini-PROTEAN systems (Bio-Rad, Milan, Italy). Gel was washed twice with citrate-phosphate/phosphate buffer (pH 5.0), and then incubated with the same buffer including 100 μM of suc-Ala-Ala-Pro-Phe-AMC. The activity of E40 was visualized in the gel exposed by UV-light.

The proteolytic activity of E40 was also evaluated by using gelatin as substrate: after electrophoretic running, PA-gel was washed with citrate phosphate buffer pH 5.0 and overlapped onto a zymogram 10% gelatin gel (Bio-rad) equilibrated with the same buffer for 10 minutes. The two overlapped gels were incubated at 37 °C for 2 hours, then the gelatin gel was stained with Coomassie Brilliant R250. Gelatin digestion was visualized after gel destaining as clear lys bands, due to proteolytic action of proteases diffused from the PA-gel to the zymogram one.

E40 stability to digestive (pepsin/trypsin) proteases. The enzymatic activity of purified E40 was evaluated in the presence of pepsin or trypsin. Aqueous solutions of enzymes, alone or in combination, (0.2 mg/ml E40, 0.1 mg/ml Pepsin or Trypsin) were diluted in citrate-phosphate/phosphate buffer containing succ-Ala-Ala-Pro-Phe-pNA at pH 4, 4.5 and 5 for pepsin, and pH 6, 7, and for trypsin assay (1–10 nM E40 final concentration). Reactions (200 μl volume in 96-wells flat bottom μtiter plates) were protracted for 110 minutes at 37 °C. Absorbance was monitored every 10 min for determining the enzymatic activity. Pepsin and trypsin without E40 were processed in the same way and tested in the same condition as reference control. Each analysis was carried out in duplicate.

Digestion of 33-mer by E40. Digestion was performed in U-bottom 96-wells microtiter plate. 33-mer was diluted in citrate phosphate buffer (pH 5) to 5 mg/ml, mixed with E40 diluted in the same buffer (1:48 enzyme vs substrate molar ratio) and incubated at 37 °C. At the time point 0, 15, 30 and 60 minute aliquots (10 μl) were taken, and reactions were stopped by boiling for 3 minutes before being analyzed by LC-MS/MS.

Samples were analyzed by HPLC system Accela Instrument (Thermo Fisher Scientific, San Jose, CA) coupled to both UV detector and LTQ-XL ion trap mass spectrometer (Thermo Fisher Scientific). Samples were diluted with 90 μl Milli-Q water and 10 μl loaded through a column Aeris Peptide 3.6 μm XB-C18 150 x 2.1 mm, Phenomenex, Torrance CA, USA). Eluent A was 0.1% acetic acid (v/v) in Milli-Q water, eluent B was acetonitrile. The separation was carried out at a flow rate of 0.2 mL/min (room temperature), with a linear gradient from 10% to 40% of solution B over 15 minutes. The column effluent was split to give a flow rate of 80 μl/min and 20 μl/min into the UV detector and ESI source respectively. The mass spectrometer operated in data-dependent mode and all spectra were acquired in the positive ionization mode with an m/z scan range of 200e2000. MS and MS/MS spectra were elaborated using the Proteome Discoverer 2.0 (Thermo Fisher).

Hydrolysis of gliadins by E40. Gliadins were extracted from whole flour of Triticum aestivum (Sagittario cultivar) according to Gianfrani et al. Gliadin (1 mg) were dissolved in 1 ml of 0.1 M ammonium acetate pH 4 and incubated with E40 enzymes (enzyme:substrate, 1:20), at 37 °C for different time points (0, 15, 30, 60, 120, 240 minutes). The enzymatic hydrolysis was stopped by boiling for 5 minutes. Samples were lyophilized and stored at −40 °C until further chemical analysis.

SDS-PAGE was performed on a Tetra-cell Mini-PROTEAN systems (Bio-Rad, Milan, Italy). Digested gliadin samples were dissolved in Laemli buffer (0.125 M Tris–HCl pH 6.8, 5% SDS, 20% glycerol, 0.02% bromophenol blue) and loaded onto precast 12% acrylamide gel (Bio-Rad). Electrophoresis was carried out under non-reducing conditions, omitting β-mercaptoethanol in the Laemli buffer. Protein bands were visualized with silver blue (Coomassie Brilliant Blue G-250) and digitalized using a LABScan scanner (Amersham Bioscience/GE Healthcare, Uppsala, Sweden).

RP-HPLC was carried out on a RP-HPLC using an HP 1100 Agilent Technology modular system (Palo Alto, CA, USA). Digested gliadin samples were suspended in 0.1% TFA and separated by C18 column (Aeris PEPTIDE, 3.6 μm, 250 x 2.10 mm i.d., Phenomenex, Torrance, CA, USA). Eluent A was 0.1% TFA (v/v) in Milli-Q water, eluent B was 0.1% TFA (v/v) in acetonitrile. The column was equilibrated at 5% B. Peptides were separated applying a linear 5–70% gradient of B over 90 minutes at a 0.2 mL/min flow rate. Chromatographic separation was performed at 37 °C, using a thermostatic column holder. The column effluent was monitored at 220 and 280 nm with an UV-Vis detector.

Hydrolysis of gliadin proteins by pepsin-trypsin/chymotrypsin and E40 and deamidation by tTG. Gliadin were suspended in 1 ml of 0.1 M ammonium acetate and digested as the scheme shown in Table 1. All enzymes were added in w/w ratio 1:20 (enzyme:protein) and incubated at 37 °C at indicated pH and
incubation time. E40/pepsin/chymotrypsin-digested gliadins were deamidated by tTGase (Sigma Aldrich), as previously described3. Briefly, the enzymatic gliadin digests (500 µg/ml) were incubated with 2 U of guinea pig tTG (5398, Sigma, St. Louis, MO, USA) at 37 °C for 2 hours in PBS with 1 mMol/L CaCl2.

**T-cell immunogenicity assays.** Gliadin-reactive T-cell lines (TCLs) were previously generated from duodenal biopsies of HLA-DQ2 CD patients. Briefly, intestinal mononuclear cells were stimulated with irradiated autologous peripheral blood mononuclear cells (PBMCs) and deamidated pepsin-chymotrypsin digested gliadin extracted from the hexaploid wheat. Growing T cells were kept in culture by repeated stimulation with heterologous irradiated PBMCs and PHA, and IL-2 as a growth factor. The peptide specificity of the TCLs was evaluated by assaying their reactivity toward a panel of immunogenic gluten peptides, and revealed a large repertoire of peptide recognition39,40. In the functional assays, the immune response of TCLs to gliadin enzymatic digests (samples A-L, Table 1) was assayed by detecting IFN-γ production. T cells (3 × 106) were co-incubated with irradiated autologous EBV-transformed, B-lymphoblastoid cell lines (B-LCLs, 1 × 105), in 200 µL of complete medium (X-Vivo15 supplemented with 5% human serum and penicillin-streptomycin antibiotics, all reagents supplied by Lonza-BioWhittaker, Verviers, Belgium) in U-bottom 96-well plates. After a 48 hours incubation, cell supernatants (50 µL) were collected for IFN-γ determination. Each antigen preparation was assayed in duplicates and in at least three independent experiments for each T-cell line. IFN-γ was measured by a classic sandwich ELISA using purified and biotin-conjugated anti-IFN-γ Abs purchased from Mabtech (Nacka Strand, Sweden). The sensitivity of the assay was 32 pg/mL−1. This study with celiac patients derived TCLs was approved by the ethical committee of SG. Moscati Hospital, Avellino Italy (Register CECTN/819 dated 03/21/2018), and Department of Pediatrics University Federico II of Naples (Register 343/17 dated 01/30/2018). All experiments were performed in accordance with relevant ethical guidelines and regulations. Informed consent for study participation was obtained for all enrolled patients.

**Evaluation of gluten by G12 competitive ELISA.** Gluten content (samples A-L, Table 1) was measured by G12 competitive ELISA, using a Ridascreen® Gliadin Elisa Kit (R-Biopharm AG Darmstadt, Germany) according to the manufacturer’s and to the AOAC guidelines.

**References**

1. Abadie, V., Sollid, L. M., Barreiro, L. B. & Jabri, B. Integration of genetic and immunological insights into a model of celiac disease pathogenesis. *Annu Rev Immunol.* **29**, 493–525 (2011).
2. Green, P. H. R., Lebwohl, B. & Greywoode, R. Celiac disease. *J. Allergy Clin. Immunol.* **135**, 1099–1106 (2015).
3. Wieser, H. Chemistry of gluten proteins. *Food Microbiol.* **24**, 115–9 (2007).
4. Shan, L. Structural basis for gluten intolerance in celiac sprue. *Science* **297**, 2275–2279 (2002).
5. Lan, S. et al. Identification and analysis of multivalent proteolytically resistant peptides from gluten: implications for celiac sprue. *J Proteome Res.* **4**, 1732–41 (2005).
6. Hausch, F., Shan, L., Santiago, N. A., Gray, G. M. & Khosla, C. Intestinal digestive resistance of immunodominant gliadin peptides. *Am. J. Physiol. Gastrointest. Liver Physiol.* **283**, C996–1003 (2002).
7. Gianfrani, C., Auricchio, S. & Troncone, R. Adaptive and innate immune responses in celiac disease. *Immunol. Lett.* **99**, 141–145 (2005).
8. Gianfrani, C. et al. Extensive in vitro gastrointestinal digestion markedly reduces the immune-toxicity of Triticum monococcum wheat: implication for celiac disease. *Mol. Nutr. Food Res.* **59**, 1844–54 (2015).
9. Kupper, C. Dietary guidelines and implementation for celiac disease. *Gastroenterology* **128**, S121–7 (2005).
10. Kurada, S., Yadav, A. & Leffler, D. A. Current and novel therapeutic strategies in celiac disease. *Expert Rev. Clin Pharmacol.* **9**, 1211–23 (2016).
11. Schuppan, D., Junker, Y. & Barisani, D. Celiac disease: from pathogenesis to novel therapies. *Gastroenterology* **137**, 1912–33 (2009).
12. Ribeiro, M. et al. Next-generation therapies for celiac disease: The gluten-targeted approaches. *Trends in Food Science & Technology* **5**, 56–71 (2018).
13. Tye-Din, J. A., Galipeau, H. J. & Agardh, D. Celiac Disease: A Review of Current Concepts in Pathogenesis, Prevention, and Novel Therapies. *Front. Pediatr.* **21**, 350 (2018).
14. Stevens, S., Murray, J. A. & Marietta, E. Celiac disease: advances in treatment via gluten modification. *Clin. Gastroenterol. Hepatol.* **10**, 859–62 (2012).
15. Bethune, M. T. & Khosla, C. Oral enzyme therapy for celiac sprue. *Methods Enzymol.* **502**, 241–71 (2012).
16. Dresselier, P., Letourneau, F., Urdaci, M. & Verneuil, B. Purification and characterization of a keratinolytic serine proteinase from Streptomyces albidoflavus. *Appl. Environ. Microbiol.* **65**, 2570–6 (1999).
17. Sakurai, Y. et al. Purification and characterization of a major collagenase from Streptomyces parvulus. *Biosc. Biotech, and Bioch.* **73**, 21–28 (2009).
18. Monciardini, P. et al. Novel members of the family Micromonosporaceae, Rugosimonospora acidiphila gen. nov. sp. nov. and Rugosimonospora africana sp. nov. *IJSEM* **59**, 2752–8 (2009).
19. Rusti, E. et al. Catenulispora acidiphila gen. nov., sp. nov., a novel, mycelium-forming actinomycete, and proposal of Catenulisporaceae fam. nov. *IJSEM* **56**, 1741–6 (2006).
20. Cavallotti, L. et al. Actinospica robiniae gen. nov., sp. nov. and Actinospica acidiphila sp. nov.: proposal for Actinospicaceae fam. nov. and Catenulisporaceae subord. nov. in the order Actinomycetales. *IJSEM* **56**, 1747–53 (2006).
21. Tamura, T., Ishida, Y., Nozawa, Y., Otaguro, M. & Suzuki, K. Transfer of Actinomadura spadix Nonomura and Ohara 1971 to Actinoallomurus spadix gen. nov., comb. nov., and description of Actinoallomurus anamensis sp. nov., Actinoallomurus caesius sp. nov., Actinoallomurus coprocola sp. nov., Actinoallomurus fulvus sp. nov., Actinoallomurus iromotensis sp. nov., Actinoallomurus luridus sp. nov., Actinoallomurus purpureus sp. nov. and Actinoallomurus yoronensis sp. nov. *IJSEM* **59**, 1867–1874 (2009).
22. Oda, K. New families of carboxyl peptidases: serine-carboxyl peptidases and glutamic peptidases. *J. Biochem.* **151**, 13–25 (2012).
23. Dressman, J. B. et al. Upper gastrointestinal (GI) pH in young, healthy men and women. *Pharm. Res.* **7**, 756–61 (1990).
24. Gardner, J. D., Ciociola, A. A. & Robinson, M. Measurement of meal-stimulated gastric acid secretion by in vivo gastric autotitration. *J. Appl. Physiol.* **92**, 427–34 (2002).
25. Morón, B. et al. Sensitive detection of cereal fractions that are toxic to celiac disease patients by using monoclonal antibodies to a main immunogenic wheat peptide. *Am. J. Clin. Nutr.* **87**, 405–14 (2008).
26. Romanos, J. et al. Analysis of HLA and non-HLA alleles can identify individuals at high risk for celiac disease. *Gastroenterology* **137**, 834–40 (2009).
27. Gass, J., Bethune, M. T., Siegel, M., Spencer, A. & Khosla, C. Combination enzyme therapy for gastric digestion of dietary gluten in patients with celiac sprue. *Gastroenterology* **133**, 472–80 (2007).

28. Wolf, C. et al. Engineering of Kuma030: A Gliadin Peptidase That Rapidly Degrades Immunogenic Gliadin Peptides in Gastric Conditions. *J. Am. Chem. Soc.* **137**, 13106–13 (2015).

29. Sollid, L. M., Qiao, S. W., Anderson, R. P., Gianfrani, C. & Koning, F. Nomenclature and listing of celiac disease relevant gluten T-cell epitopes restricted by HLA-DQ molecules. *Immunogenetics* **64**, 455–60 (2012).

30. Siegel, M. et al. Rational design of combination enzyme therapy for celiac sprue. *Chem Biol.* **13**, 649–58 (2006).

31. Lähdeaho, M. L. et al. Glutenase ALV003 attenuates gluten-induced mucosal injury in patients with celiac disease. *Gastroenterology* **146**, 1649–58 (2014).

32. Gordon, S. R. et al. Computational design of an α-gliadin peptidase. *J. Am. Chem. Soc.* **134**, 20513–20 (2012).

33. König, J., Holster, S., Bruins, M. J. & Brummer, R. J. Randomized clinical trial: Effective gluten degradation by Aspergillus niger-derived enzyme in a complex meal setting. *Sci. Rep.* **7**, 13100 (2017).

34. Hopwood, D. A., Kieser, T., Wright, H. M. & Bibb, M. Plasmids, recombination and chromosome mapping in Streptomyces lividans. *J. Gen Microbiol.* **129**, 2257–2269 (1983).

35. König, J., Holster, S., Bruins, M. J. & Brummer, R. J. Randomized clinical trial: Effective gluten degradation by Aspergillus niger-derived enzyme in a complex meal setting. *Sci. Rep.* **7**, 13100 (2017).

36. Catassi., C. et al. Non-Celiac Gluten sensitivity: the new frontier of gluten related disorders. *Nutrients* **5**, 3839–53 (2013).

37. Anné, J., Vrancken, K., Van Mellaert, L., Van Impe, J. & Bernaerts, K. Protein secretion biotechnology in Gram-positive bacteria with special emphasis on Streptomyces lividans. *Biochimica et Biophysica Acta (BBA) - Molecular Cell Research.* **1843**(8), 1750–1761 (2014).

38. Kieliszek, M. & Misiewicz, A. Microbial transglutaminase and its application in the food industry. A review. *Folia Microbiologica.* **59**, 241–250 (2013).

39. Camarca, A. et al. Intestinal T cell responses to gluten peptides are largely heterogeneous: implications for a peptide-based therapy in celiac disease. *J Immunol.* **182**(7), 4158–66 (2009).

40. Camarca, A. et al. Gliadin-reactive T cells in Italian children from preventCD cohort at high risk of celiac disease. *Pediatr Allergy Immunol.* **28**(4), 362–369 (2017).

Acknowledgements

We acknowledge Dr. Maria Cristina Comelli for her critical contribution to this study. This work was funded by Nemysis Limited, Dublin Ireland. The funder had no role in study design, data collection and analysis, and preparation of the manuscript. C.G. is member of the Advisory Board for Nemysis Limited.

Author Contributions

L.C., C.G. and G.M.: conceived and planned the experiments, secured funding, and wrote the manuscript. A.T., L.C., G.C., A.S. and N.S.: performed characterization, cloning expression and purification of the enzyme. S.D.C. and L.D.S.: performed the proteomic analysis; S.P. and M.L.: performed the immunogenic analysis. R.T.: enrolled CD patients, and contributed to immunogenic analysis and project discussion.

Additional Information

Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-48299-7.

Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019